Opportunity for Improved Menopausal Hormone Therapy Prescribing
This Perspective discusses the implications of the recent US Food and Drug Administration (FDA) label change on menopausal hormone therapy for clinicians to better integrate hormone therapy options and personalized, shared decision-making to improve care for midlife women.
Authors
- A Tadikonda (ORCID: https://orcid.org/0000-0002-7814-9919)
- James Manson
- Deborah Bartz
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1001/jama.2026.1891
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00